Design Therapeutics (DSGN) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 9, 2026, to be held virtually for all shareholders of record as of April 14, 2026.

• Shareholders will vote on the election of one Class II director and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026.

• Proxy materials are available online, and voting can be done via internet, phone, or mail.

• The Board encourages all shareholders to participate and provides detailed instructions for voting and meeting attendance.

Voting matters and shareholder proposals

• Proposal 1: Election of Simeon George, M.D., as Class II director for a three-year term expiring at the 2029 Annual Meeting.

• Proposal 2: Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Shareholders may submit proposals for the 2027 Annual Meeting by December 28, 2026, for inclusion in proxy materials.

• Voting instructions and procedures are provided for both record holders and beneficial owners.

Board of directors and corporate governance

• Board consists of seven members divided into three classes, with a focus on diversity and relevant industry experience.

• 43% of directors are women or racially/ethnically diverse.

• Majority of directors are independent per Nasdaq standards; Dr. Shah is not independent due to his executive role.

• Board leadership structure includes a combined Chairperson/CEO role and a Lead Independent Director to ensure balanced oversight.

• Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Research and Development.